{"id":"W4395664784","doi":"10.1097/hc9.0000000000000426","title":"Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial","year":2024,"lang":"en","type":"article","venue":"Hepatology Communications","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Medical Research Council; Ipsen; Department of Health and Social Care; Cancer Research UK; Wellcome Trust; Health and Social Care Research and Development Division; Novo Nordisk; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Pfizer; National Institute for Social Care and Health Research; Gilead Sciences; GlaxoSmithKline; Birmingham Biomedical Research Centre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Primary sclerosing cholangitis; Blockade; Medicine; Fibrosis; Adhesion; Monoclonal antibody; Gastroenterology; Internal medicine; Biliary tract; Liver fibrosis; Antibody; Pathology; Immunology; Disease; Receptor; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002744932,0.001976469,0.003023429,0.0003432157,0.0004506976,0.001307633,0.0008429579,0.001784177,0.003346343],"category_scores_gemma":[0.001371555,0.0005489651,0.001473349,0.00044696,0.00114236,0.0009650716,0.0003647627,0.00275128,0.0007588623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007612917,"about_ca_system_score_gemma":0.001586474,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004410063,"about_ca_topic_score_gemma":0.001097395,"domain_scores_codex":[0.9992419,0.0003988141,0.00004072826,0.0001050824,0.00007001491,0.0001433741],"domain_scores_gemma":[0.9988033,0.0002382533,0.0002963131,0.000107577,0.0001001499,0.0004543669],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9260684,0.02454191,0.002350708,0.001094188,0.00111774,0.0001439548,0.0001486387,0.0008978012,0.01250549,0.0001547406,0.001750313,0.02922611],"study_design_scores_gemma":[0.8527882,0.1428664,0.002371625,0.00002770266,0.0001845,0.00008751269,0.00001662267,0.0003794601,0.0007384268,0.00007509968,0.000453809,0.00001061111],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989697,0.004183774,0.0006524055,0.0006632109,0.0002318631,0.002482486,0.0008020957,0.0001064401,0.001180733],"genre_scores_gemma":[0.9879347,0.002408334,0.001304024,0.001040818,0.0004660706,0.003921498,0.001292598,0.00002168433,0.001610317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003346343,"threshold_uncertainty_score":0.01451671,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1235209284734993,"score_gpt":0.3727805712484096,"score_spread":0.2492596427749103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}